Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
03/2009
03/19/2009WO2009033722A2 Use of a octreotide as a therapeutic agent
03/19/2009WO2009033721A2 Use of salusin beta alone or in combination with octreotide as a therapeutic agent
03/19/2009WO2009033720A1 Mastoparan for the treatment of diseases
03/19/2009WO2009033719A2 Use of a deslorelin and mastoparan as a therapeutic agent
03/19/2009WO2009033718A2 Use of anti -inflammatory peptide 1 as a therapeutic agent
03/19/2009WO2009033717A2 Use of gonadorelin as a therapeutic agent
03/19/2009WO2009033714A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033712A2 Use of melanotan ii as a therapeutic agent
03/19/2009WO2009033711A2 Use of glp-1 as a therapeutic agent
03/19/2009WO2009033710A1 Use of peptide yy, alone or in combination with glucagon-like peptide, for use in medicine
03/19/2009WO2009033707A2 Use of retrocyclin-1 as a therapeutic agent for the treatment of hcmv infections
03/19/2009WO2009033701A1 Use of urodilatin as a therapeutic agent
03/19/2009WO2009033700A1 Use of secretin and optionally urodilatin as therapeutic agents
03/19/2009WO2009033696A1 Use of a peptide pyx-1 as a therapeutic agent
03/19/2009WO2009033692A2 Use of the peptides fibrinopeptide a and pyx-i as a therapeutic agents
03/19/2009WO2009033690A1 Bfgf (119-126) for therapeutic applications
03/19/2009WO2009033687A1 Spantide ii and bfgf (119-126) for therapeutic applications
03/19/2009WO2009033684A1 Minigastrin as a therapeutic agent
03/19/2009WO2009033681A2 Cyclo-argd as a therapeutic agent
03/19/2009WO2009033680A2 Galanin-like peptide alone or in combination with cyclo-argd as a therapeutic agent
03/19/2009WO2009033678A2 Use of a tuftsin as a therapeutic agent
03/19/2009WO2009033669A2 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys-oh as a therapeutic agent
03/19/2009WO2009033668A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033667A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033666A2 Use of parathyroid hormone ( 1-34 ) as anti-hiv agent
03/19/2009WO2009033665A2 Use of a rgd-peptide and/or parathyroid hormone (1-34 ) as anti-hiv agent
03/19/2009WO2009033664A1 Use of delta-endorphin as a therapeutic agent
03/19/2009WO2009033663A1 Use of fertirelin and delta-endorphin as therapeutic agents
03/19/2009WO2009033661A2 Use of rgdspasskp and optionally angiotensin ii as therapeutic agents in the treatment of eg s. pneumoniae infections
03/19/2009WO2009033660A2 Use of octreotide as a therapeutic agent
03/19/2009WO2009033658A1 (d-leu7 ) -histrelin as a therapeutic agent
03/19/2009WO2009033657A2 Use of trp6-triptorelin and d-leu6-leuprolide as therapeutic agents
03/19/2009WO2009033656A2 Use of follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumoniae infection
03/19/2009WO2009033561A1 Substituted 6-phenylnicotinic acids and the use thereof
03/19/2009WO2009005646A3 Substituted piperazines as cb1 antagonists
03/19/2009WO2009000296A3 Tpp ii inhibitors for use in the treatment of autoimmune and inflammatory diseases and transplant rejection
03/19/2009WO2008152226A3 Homogeneous and stable composition rich in oleaginous substances based on a milk product, method for the preparation thereof and uses thereof
03/19/2009WO2008149379A3 Novel compounds
03/19/2009WO2008147807A3 Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
03/19/2009WO2008116107A3 Piperazine derivatives as glucokinase activators
03/19/2009WO2008078176A9 Methods, compounds, and compositions for treating metabolic disorders and diabetes
03/19/2009US20090076151 Method for stimulating weight loss and/or for lowering triglycerides in patients
03/19/2009US20090076140 Pharmaceutical compositions containing sulphonic acid derivatives
03/19/2009US20090076136 Therapeutic agent
03/19/2009US20090076129 Methods and related compositions using specific flavonoids and indanes to reduce weight and inhibit lipase, alpha-amylase and alpha-glucosidase activity in mammals
03/19/2009US20090076125 Deuterium-enriched glimepiride
03/19/2009US20090076122 PARP Modulators and Treatment of Cancer
03/19/2009US20090076114 Cis-1,2-substituted stilbene derivatives and their use in preparation of drugs for treatment and/or prevention of diabetes
03/19/2009US20090076111 Methods for improving glycemic control in humans
03/19/2009US20090076106 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels
03/19/2009US20090076102 Deuterium-enriched muraglitazar
03/19/2009US20090076101 Thiophene and Thiazole Substituted Trifluoroethanone Derivatives as Histone Deacetylase (HDAC) Inhibitors
03/19/2009US20090076093 Deuterium-enriched rosiglitazone
03/19/2009US20090076068 Imidazopyridin-2-one derivatives as inhibitors of lipases and phospholipases
03/19/2009US20090076062 Organic Compounds
03/19/2009US20090076029 Compounds and Methods for Treating Obesity
03/19/2009US20090076014 For administration with food; bioavailability
03/19/2009US20090076013 Deuterium-enriched sitagliptin
03/19/2009US20090075992 Pteridine Derivatives as Nitric Oxide Synthase Activators
03/19/2009US20090075981 INHIBITORS OF p38
03/19/2009US20090075975 Arylsulfonamides and uses related thereto
03/19/2009US20090075968 CETP inhibitors
03/19/2009US20090075957 Xanthohumol compositions and methods of using same
03/19/2009US20090075913 Glycoside having 4-methylergost-7-en-3-ol skeleton and hyperglycemia improving agent
03/19/2009US20090075904 Protein Hydrolysate Enriched In Peptides Inhibiting DPP-IV And Their Use
03/19/2009US20090075890 Long lasting synthetic exendin-4 peptide conjugates and methods of use thereof
03/19/2009US20090075873 Gastrin compositions and formulations, and methods of use and preparation
03/19/2009US20090075864 Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
03/19/2009US20090075327 Methods for improving secondary metabolite production in fungi
03/19/2009US20090074895 Composition and uses thereof
03/19/2009US20090074883 Multivitamin and Mineral Compositions for Individuals Having Renal Disease
03/19/2009US20090074882 Insulin compositions and method of making a composition
03/19/2009US20090074859 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
03/19/2009US20090074847 Transport System In Biological Systems
03/19/2009US20090074769 Glp-1 analog fusion proteins
03/19/2009US20090074751 Growth factor fraction compositions and methods
03/19/2009US20090074734 Microbial intestinal delivery of obesity related peptides
03/19/2009US20090074722 Products and methods for treating PTP lar diseases
03/19/2009US20090074708 Inhibitors and Enhancers of Uridine Diphosphate-Glucuronosyltransferase 2B (UGT2B)
03/19/2009CA2731204A1 Use of a peptide as a therapeutic agent
03/19/2009CA2704726A1 Use of a defensin peptide as a therapeutic agent
03/19/2009CA2699472A1 Polymorph forms of (s)-2-((4-benzofuranyl)carbonylaminomethyl)-1-((4-(2-methyl-5-(4-fluorophenyl)thiazolyl)carbonyl)piperidine
03/19/2009CA2699403A1 Pharmaceutical composition with anti-diabetic action
03/19/2009CA2699382A1 Modulators of cystic fibrosis transmembrane conductance regulator
03/19/2009CA2699285A1 Process for the preparation of compounds useful as inhibitors of sglt
03/19/2009CA2699222A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699215A1 (d-leu7 ) -histrelin as a therapeutic agent
03/19/2009CA2699167A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699026A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699020A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699012A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699010A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699008A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699006A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698992A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698985A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698984A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698981A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698980A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698978A1 Use of human neuropeptide af as a therapeutic agent
1 ... 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 ... 1298